https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52963 Wed 28 Feb 2024 16:09:43 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45096 + lineage markers and their expression of immune checkpoint pathway proteins. To confirm these findings, four stem/progenitor marker expression patterns were compared with CD4, CD8 and CD20 in a ccRCC TMA which showed a number of similar trends with respect to frequency of the different tumourinfiltrating leukocytes. Conclusion: Taken together, we observed heterogeneous but patterned expression levels of different stem/ progenitor markers. Our results suggest a non-random relationship between their expression patterns with the immune microenvironment populations in ccRCC.]]> Wed 26 Oct 2022 12:58:25 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29578 Wed 17 Nov 2021 16:29:30 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29771 P<0.0001). Delayed response post first scan was seen in 2 out of 37 (5%) deemed progressive (PD) by RECIST and 2 out of 14 (14%) deemed PD by irRC. Modified CHOI criteria showed response of 38% (14 out of 37). Change in tumour size and density on first follow-up assessment was associated with OS with each 1000 mm² increase in tumour size from baseline increasing the hazard of dying by 25.9% (HR=1.259, (95% CI=1.116-1.420), P=0.0002). Similarly, each 20HU increase in density increased the HR by 15% (HR=1.15, (95% CI 1.045-1.260), P=0.004). Response defined by any criteria had superior OS (CHOI P=0.0084; mCHOI P=0.0183; irRC P<0.0001 and RECIST P=0.0003). Conclusions: Response by any criterion was prognostic. Novel patterns of response and changes on treatment in tumour density suggest complex anti-tumour responses to immunotherapy.]]> Wed 11 Apr 2018 12:06:49 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:30091 Wed 11 Apr 2018 12:04:08 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29495 Wed 11 Apr 2018 10:17:20 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24837 Wed 10 Nov 2021 15:13:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50154 Wed 05 Jul 2023 14:26:05 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36640 Tue 25 Oct 2022 09:27:51 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47980 Tue 21 Mar 2023 16:56:35 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35482 Thu 17 Mar 2022 14:40:58 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32094 Thu 17 Mar 2022 14:40:51 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48408 Thu 16 Mar 2023 14:04:23 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:40073 Thu 14 Jul 2022 13:32:13 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34616 Thu 04 Nov 2021 10:39:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:19810 Sat 24 Mar 2018 07:57:12 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:24857 Sat 24 Mar 2018 07:11:21 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50637 Mon 31 Jul 2023 16:21:11 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38260 9-tetrahydrocannabinol (∆⁹-THC). Evidence is emerging for the therapeutic benefits of cannabis in the treatment of neurological and neurodegenerative diseases, with potential efficacy as an analgesic and antiemetic for the management of cancer-related pain and treatment-related nausea and vomiting, respectively. An increasing number of preclinical studies have established that ∆⁹-THC can inhibit the growth and proliferation of cancerous cells through the modulation of cannabinoid receptors (CB1R and CB2R), but clinical confirmation remains lacking. In parallel, the anti-cancer properties of non-THC cannabinoids, such as cannabidiol (CBD), are linked to the modulation of non-CB1R/CB2R G-protein-coupled receptors, neurotransmitter receptors, and ligand-regulated transcription factors, which together modulate oncogenic signalling and redox homeostasis. Additional evidence has also demonstrated the anti-inflammatory properties of cannabinoids, and this may prove relevant in the context of peritumoural oedema and the tumour immune microenvironment. This review aims to document the emerging mechanisms of anti-cancer actions of non-THC cannabinoids.]]> Mon 29 Jan 2024 17:45:13 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31921 Mon 23 Sep 2019 10:59:24 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54742 Mon 11 Mar 2024 14:26:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39586 in silico using the Kaplan-Meier Plotter (n=3,935), the TCGA invasive breast carcinoma (n=960) and GOBO (n=821) data sets. Functional effects of BAALC expression on breast cancer proliferation, migration and invasion were determined in vitro. We demonstrate herein that BAALC expression is progressively increased in primary and breast cancer metastases when compared to normal breast tissue. Increased BAALC mRNA is associated with a reduction in DMFS and disease-free survival, but not OS, in breast cancer patients, even when corrected for tumor grade. We show that overexpression of BAALC in MCF-7 breast cancer cells increases the proliferation, anchorage-independent growth, invasion, and migration capacity of these cells. Conversely, siRNA knockdown of BAALC expression in Hs578T breast cancer cells decreases proliferation, invasion and migration. We identify that this BAALC associated migration and invasion is mediated by focal adhesion kinase (FAK)-dependent signaling and is accompanied by an increase in matrix metalloproteinase (MMP)-9 but not MMP-2 activity in vitro. Our data demonstrate a novel function for BAALC in the control of breast cancer metastasis, offering a potential target for the generation of anti-cancer drugs to prevent breast cancer metastasis.]]> Mon 08 Aug 2022 11:48:18 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42246 P = 0.001) was associated with increased odds (OR = 4.5) of being offered biobanking. The majority did not know what occurred to samples after surgery (59.3%) or pathology review (81.4%) and ability to answer these questions was associated with discussion of participation (P < 0.001). Of the few outpatients who discussed biobanking with their doctor (29%), all consented. Conclusion: Professional‐initiated, opt‐in consent resulted in a few educated patients being approached; greater professional initiation of consent would be fruitful as most patients were willing to participate if asked. However, other consent approaches minimizing professional involvement were as acceptable to participants warranting further consideration.]]> Fri 26 Aug 2022 09:40:53 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51948 Fri 22 Sep 2023 17:06:07 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36624 Fri 21 Oct 2022 12:10:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44106 Fri 07 Oct 2022 13:58:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25061 80 %. Culture in serum-free conditions selected for growth of normal renal proximal tubule epithelial cells. Transcriptional profiling of ccRCC and matched normal cell cultures identified up- and down-regulated networks in ccRCC and comparison to The Cancer Genome Atlas confirmed the clinical validity of our cell cultures. Conclusions: The ability to establish primary cultures of ccRCC cells and matched normal kidney epithelial cells from almost every patient provides a resource for future development of novel therapies and personalized medicine for ccRCC patients.]]> Fri 03 Dec 2021 10:33:37 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:49686 Fri 02 Jun 2023 12:33:56 AEST ]]>